First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

OncoAlert and ecancer - ESMO 2021 Day 2

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer

ESMO President: What to watch for at ESMO 2021

OncoAlert and ecancer weekly round up for August 23rd - August 29th, 2021

OncoAlert and ecancer weekly round up for August 2 - August 14, 2021

OncoAlert and ecancer weekly round up for July 26 - August 1, 2021

Targeted therapy for breast cancer

Triple negative breast cancer: OlympiA study